130A Stock Overview
Engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Veritas In Silico Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥905.00 |
| 52 Week High | JP¥3,475.00 |
| 52 Week Low | JP¥637.00 |
| Beta | 0 |
| 11 Month Change | -5.43% |
| 3 Month Change | -17.50% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 130A | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 0.6% | -2.1% | -0.4% |
| 1Y | n/a | -22.6% | 11.4% |
Return vs Industry: Insufficient data to determine how 130A performed against the JP Life Sciences industry.
Return vs Market: Insufficient data to determine how 130A performed against the JP Market.
Price Volatility
| 130A volatility | |
|---|---|
| 130A Average Weekly Movement | 8.4% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 130A's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 130A's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Shingo Nakamura | www.veritasinsilico.com |
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. It has strategic partnership with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. The company was incorporated in 2016 and is based in Shinagawa, Japan.
Veritas In Silico Inc. Fundamentals Summary
| 130A fundamental statistics | |
|---|---|
| Market cap | JP¥5.76b |
| Earnings (TTM) | JP¥0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 130A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 130A income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥0 |
| Earnings | JP¥0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 130A perform over the long term?
See historical performance and comparison